---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-23-000088"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:50:33.406506+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q3 net loss $64M, cash $1B; vepdegestrant Phase 3 on track for 2H 2024

## Summary
- Q3 2023 net loss $64.0M vs $66.2M prior year; revenue $34.6M from collaborations.
- Cash, cash equivalents and marketable securities $1.004B as of Sept 30, 2023; runway into 2026.
- VERITAC-2 Phase 3 trial of vepdegestrant in 2L+ ER+/HER2- breast cancer enrollment ongoing; top-line data 2H 2024.
- Prioritized ARV-766 over bavdegalutamide for Phase 3 in mCRPC based on broader efficacy and superior tolerability.
- Plan to submit two IND/CTA applications for BCL6 (oncology) and LRRK2 (neuroscience) PROTAC degraders by year-end 2023.

## SEC filing metadata
- accession: 0001655759-23-000088
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/0001655759-23-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/arvn-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-23-000088
- JSON: https://secwatch.observer/filing/0001655759-23-000088.json
- Plain text: https://secwatch.observer/filing/0001655759-23-000088.txt

## Key facts
- Earnings Releases
  ARVINAS, INC. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/0001655759-23-000088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.